Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020672 (hypothermia)
 17,327 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The pharmacological effects of the new platelet aggregation inhibitor cilostazol (6-(4-(1-cyclohexyl-1 H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC-13013) on the central nervous system were studied. Cilostazol had little effect on the general behavior of mice up to a dose of 1000 mg/kg p.o. and caused disappearance of pinna reflex, alertness and startle response and slight ptosis in only one of 6 rats at a dose of 1000 mg/kg p.o. Cilostazol had little effect on spontaneous movement and motor coordination in mice and did not potentiate hexobarbital-induced hypnosis, antagonize methamphetamine-induced hypermotor activity, cause muscle relaxation or have an anticonvulsant effect. Cilostazol did not affect normal body temperature but slightly antagonized reserpine-induced hypothermia at 300 mg/kg p.o. in mice. Cilostazol did not show an analgesic effect by Haffner's method, but it did slightly inhibit acetic acid-induced writhing at doses higher than 300 mg/kg p.o. in mice. The inhibitory effect was considered to be due to its peripheral effect. Cilostazol had little effect on discriminated avoidance response in rats, EEG arousal response in rabbits or spinal reflex in cats. However, it did slightly increase the slow wave until about 2 h after administration at 1000 mg/kg p.o., but the slow-wave sleep period did not tend to persist for a long period. These results suggest that cilostazol had little effect on the central nervous system.
 ...
PMID:General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system. 407 29

Concentrations of serotonin and of its metabolite 5-hydroxyindolyl acetic acid (5-HIAA) were shown to increase in rat brain stem after short-term hypothermia. At the same time, no distinct alterations could be found in the activity and kinetic parameters of the brain monoamine oxidase enzymatic system (MAO) catalyzing oxidative deamination of serotonin. Reduction of body temperature was accompanied by an increase in the MAO activity with serotonin as a substrate due to elevation in the enzyme-substrate affinity. Complete restoration of serotonin metabolism occurred within several days.
 ...
PMID:[Effect of short-term hypothermia on the monoamine oxidase system in the rat brain]. 618 83

Coixol (6-methoxybenzoxazolone) contained in Coix Lachryma-Jobi L. var. ma-yuen Stapf was compared with chlorzoxazone with respect to behavioral and EEG effects in mice and rats. Coixol 50-100 mg/kg, i.p. decreased locomotor activities of both species and produced hypothermia in rats. These effects of coixol were the same in potency as chlorzoxazone given in the same dose. Coixol was approximately twice as potent as chlorzoxazone in potentiating thiopental-induced sleep. This compound attenuated the writhing syndrome induced by 1% acetic acid and increased the threshold to jumping response induced by foot shock, to the same degree as seen with chlorzoxazone. Coixol was equipotent to chlorzoxazone in preventing convulsions induced by maximal electro-shock, while it was about 1.5 times more potent than chlorzoxazone in suppressing pentylenetetrazol-induced convulsion. Coixol 20-100 mg/kg inhibited the lever pressing response of hypothalamic self-stimulation in rats. In rats with chronically implanted electrodes, coixol 50-100 mg/kg induced drowsy patterns on the spontaneous EEG. The EEG arousal response to the external auditory stimulation was inhibited by the same doses of coixol, whereas it failed to suppress the arousal response to the midbrain reticular stimulation. These results indicate that coixol has pharmacological properties qualitatively similar to chlorzoxazone and acts as a central muscle relaxant with an anti-convulsant effect.
 ...
PMID:[Behavioral and EEG effects of coixol (6-methoxybenzoxazolone), one of the components in Coix Lachryma-Jobi L. var. ma-yuen Stapf]. 705 57

The general pharmacology of afloqualone, a new centrally acting muscle relaxant, in the CNS was examined in mice and rats and findings compared with those of other central muscle relaxants. Afloqualone showed relatively strong hexobarbital and barbital anesthesia potentiating action. Taking into account the dose ratio of anesthesia potentiating action to the muscle relaxing action, however, the potency of anesthesia potentiating action of afloqualone is lower than that of chlormezanone. At doses producing muscle relaxing action, afloqualone inhibited spontaneous motor activity, methamphetamine-induced hypermotility, pentylenetetrazol-, nicotine-, and maximum electroshock-convulsions, fighting episodes in foot-shocked mice, conditioned avoidance response in rat pole-climbing test, and acetic acid-induced writhing syndrome and lowered normal body temperature. The dose ratios of these pharmacological actions to muscle relaxing action of afloqualone, however, were larger than those of chlormezanone and mephenesin. This suggests that the central depressant activity of afloqualone is less potent and the specificity of muscle relaxing action of afloqualone is higher than those of climbing behaviour, physostigmine-induced death, serotonin-induced heat twitch, and reserpine-induced hypothermia, even at 50 mg/kg. Tolperisone showed neither muscle relaxing action nor other central actions when administered orally.
 ...
PMID:[General pharmacology of 6-amino-2-fluoromethyl-3-(o-tolyl)-4(3H)-quinazolinone (afloqualone), a new centrally acting muscle relaxant. I. Effects on the central nervous system (author's transl)]. 732 55

General pharmacological effects of T-3761, a new oral quinolone antibacterial agent, on the central nervous system were investigated in laboratory animals. The results obtained are summarized as follows. 1. T-3761 exerted no significant effects on spontaneous motor activity, motor coordination, pentobarbital-induced hypnosis, electroshock-, pentetrazole- or strychnine-induced convulsion, acetic acid-induced writhing responses, reserpine-induced hypothermia and ptosis in mice at oral doses of 100, 300 and 1,000 mg/kg. The same oral doses of T-3761 exerted no significant effects on body temperature and passive avoidance response in rats. 2. T-3761 had no effects on EEG in cats and spinal reflex in rats at intravenous doses of 10, 30 and 100 mg/kg. 3. Convulsions were not observed in mice after any oral combinations of T-3761 at a dose of 200 or 1,000 mg/kg with 14 different nonsteroidal anti-inflammatory drugs (NSAIDs) including fenbufen. 4. An oral combination of T-3761 even at a higher doses of 3,000 mg/kg with 4-biphenylacetic acid (BPAA) which is a principally active metabolite of fenbufen also did not induce convulsions in mice. 5. T-3761 did not inhibit GABA receptor binding in rat brain synaptic membranes at 10(-4) M in either the absence or presence of BPAA. These results suggest that T-3761 is an antibacterial agent which would be unlikely to produce any side effects on the central nervous system and to produce convulsion when combined with NSAIDs in clinical use.
 ...
PMID:[General pharmacology of T-3761, a new oral quinolone antibacterial agent (1). Effect on the central nervous system]. 763 4

Leaf and bark extracts of Byrsonima crassifolia displayed concentration-dependent, spasmogenic effects on rat fundus in vitro and biphasic effects on rat jejunum and ileum in vitro. Dose-related in vivo effects in intact rats using hippocratic screening were: decrease in motor activity, mild analgesia, back tonus, enophthalmos, reversible palpebral ptosis, ear blanching, Robichaud positive, catalepsy (awake) and strong hypothermia. Rat fundus in vitro was used as the bioassay to carry out an activity-directed separation. Bioactive material was concentrated in a 2% acetic acid leaf extract (HOAcE). Potency of HOAcE was increased by the presence of pargyline in the bathing solution. HOAcE was antagonized noncompetively by 1(1-naphthyl) piperazine (1-NP) and cyproheptadine and antagonized competitively by atropine (ATR). Cumulative concentration-response curves of HOAcE and serotonin (5-HT) did not show significant departure from parallelism (P > 0.1) and 5-HT potency was 6040 times that of HOAcE (95% confidence limits: 4620-7850). Solvent extraction of HOAcE split the spasmogenic activity of HOAcE into two types: (i) high-efficacy, low-potency, n-butanol-extracted, pargyline- and 1-NP-sensitive, ATR-insensitive activity, and (ii) low-efficacy, high-potency, ethyl acetate-extracted, pargyline-insensitive, ATR- and 1-NP-sensitive activity. HOAcE lacked muscarinic and nicotinic effects on rat jejunum and frog rectus abdominis. Results suggest the presence of more than one spasmogenic compound in the plant.
 ...
PMID:Pharmacological and chemical screening of Byrsonima crassifolia, a medicinal tree from Mexico. Part I. 841 47

The substituted amphetamine 3,4-methylenedioxymethamphetamine (MDMA) has been shown to be neurotoxic to serotonin (5HT) terminals in the rat, and rat body temperature (TEMP) has been shown to affect this neurotoxicity. This study looked at the effect on CORE TEMP of three drugs that protect against MDMA neurotoxicity in the rat. Male Holtzmann rats were injected with a control saline (SAL) injection or with ketanserin (KET; 6 mg/kg), alpha-methyl-p-tyrosine (AMPT; 75 mg/kg) or fluoxetine (FLUOX; 10 mg/kg) before a 40-mg/kg MDMA or SAL injection. CORE TEMP was recorded throughout the study using a noninvasive peritoneally implanted temperature probe. Rats pretreated with KET had no change in CORE TEMP until MDMA was injected, at which time an immediate hypothermia was seen that continued for 180 minutes, with a peak low of 34.7 degrees C. Rats treated with AMPT had no change in CORE TEMP until the MDMA was injected, at which time an immediate hypothermia was seen that continued for 240 min., with a peak low of 34.3 degrees C. Two weeks later, brain regions were analyzed for 5-HT and 5-hydroxindole acetic acid levels. MDMA produced significant (P < .05) decreases in 5-HT and 5-hydroxindole acetic acid levels in the frontal cortex, somatosensory cortex, striatum and hippocampus, and pretreatment with KET or AMPT prevented these depletions. When rats were given the KET/MDMA or AMPT/MDMA drug injections and warmed to prevent hypothermia, the protection against neurotoxicity was removed, which indicated that the hypothermia mediated the protective effects of KET and AMPT. In comparison with the hypothermia seen with AMPT or KET pretreatment, pretreatment with FLUOX had no effect on CORE TEMP. The rats given the FLUOX/MDMA treatment did not have different CORE TEMPs than rats given SAL/MDMA. The FLUOX pretreatment protected against MDMA-induced 5-HT and 5-hydroxindole acetic acid depletions in the frontal cortex, somatosensory cortex, striatum and hippocampus. This study suggests that a decrease in CORE TEMP may be a mechanism of protection against MDMA neurotoxicity by some drugs but that there is also a mechanism of protection that is independent of a change in body temperature.
 ...
PMID:Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. 876 59

Three new neurotropic sesquiterpenoids, veranisatins A, B and C, were isolated from star anise (Illicium verum Hook. fil., Illiciaceae). Veranisatins showed convulsion and lethal toxicity in mice at a dose of 3 mg/kg (p.o.), and at lower doses they caused hypothermia. Veranisatin A and the related compound, anisatin, were tested for the other pharmacological activities such as locomotor activity and analgesic effect. Both compounds decreased the locomotion enhanced by methamphetamine at oral doses of 0.1 and 0.03 mg/kg, respectively, and demonstrated the analgesia on acetic acid-induced writhing and tail pressure pain at almost similar doses.
 ...
PMID:Neurotropic components from star anise (Illicium verum Hook. fil.) 890 18

1. The effect of tryptophan on body temperature was studied in rats pretreated with pargyline, an irreversible monoamine oxidase inhibitor (MAOI), and harmaline, a reversible MAOI. 2. Tryptophan (100 mg/kg IP) produced hypothermia followed by hyperthermia in pargyline-pretreated rats, and hypothermia in harmaline-pretreated rats, but tryptophan did not cause body temperature changes by itself. 3. The tryptophan-induced hypo- and hyperthermic effects, which peaked at about 1 and 6 hr after tryptophan administration, respectively, were accompanied by a significant increase in serotonin (5-HT) levels in the pargyline-pretreated rat brain (75%-138.7% and 207%-240.9% increase, respectively), and the 5-HT levels in the hyperthermic state were significantly higher than those in the hypothermic state. 4. In harmaline-pretreated rats, tryptophan also increased the central 5-HT levels (80.5%-95.5% increase) in the hypothermic state, and the effect peaked at about 1 hr after tryptophan administration. The central 5-HT levels in harmaline-pretreated rats slightly decreased at 6 hr after tryptophan administration and were significantly lower than those in the hyperthermic state in the pargyline-pretreated rats. 5. Tryptophan (100 mg/kg IP) administration decreased 5-hydroxy indole acetic acid (5-HIAA) levels, 5-HT turnover, and dopamine (DA) turnover in the brain of pargyline-pretreated rats, but these parameters were not significantly different between the hypothermic and hyperthermic states (i.e., at 1 and 6 hr after tryptophan administration, respectively). 6. These results suggest that the tryptophan-induced body temperature change depends on the different 5-HT levels in the brain and that the 5-HT level needed to induce hyperthermia is higher than that needed to induce hypothermia.
 ...
PMID:Central serotonin level-dependent changes in body temperature following administration of tryptophan to pargyline- and harmaline-pretreated rats. 906 81

The pharmacokinetics of the hepatobiliary transport of an anionic drug, 7,8-dihydro-5-[(E)-[[a-(3-pyridyl)-benzylidene]aminooxy]ethyl]-1- naphthyloxy]acetic acid (ONO-1301), a new prostaglandin (PG) I2 receptor agonist, was investigated in rats. During intravenous infusion of this compound, the drug concentrations in arterial blood, hepatic vein and liver and the biliary excretion rate were measured at steady state. At a low infusion rate, 30% of the ONO-1301 was extracted by the liver during a single pass, and the main clearance organ was demonstrated to be the liver. The total clearance, Cltot; hepatic extraction ratio, EH; and liver-to-plasma concentration ratio, Kp values, decreased as the infusion rate increased. Considering the infusion rate-dependent decrease in all three parameters, saturation of hepatic uptake was suggested to be the cause of the nonlinear pharmacokinetics. To confirm this hypothesis, the time profiles of the plasma and liver concentrations of ONO-1301 after intravenous administration of various doses (0.01-25 mg/kg) were analyzed in vivo. The early-phase hepatic uptake clearance at lower doses (0.01-1 mg/kg) was 28 ml/min/kg, which is close to the hepatic plasma flow rate. The uptake clearance also was decreased at the higher doses. The uptake mechanism was investigated with isolated rat hepatocytes. Both Na(+)-dependent and -independent uptake were observed and these were inhibited by hypothermia and ATP depletors, which suggests that the uptake is via carrier-mediated active transport. The initial uptake velocity exhibited concentration dependence, and the kinetic parameters were as follows: Km, 15.6 microM (Na(+)-dependent) and 3.8 microM (Na(+)-independent); Vmax, 5.9 nmol/min/mg (Na(+)-dependent) and 4.8 nmol/min/mg (Na(+)-independent). With these in vitro transport parameters, the plasma unbound fraction and the hepatic plasma flow rate, the hepatic uptake clearance was calculated from a mathematical model. The calculation also indicated that the uptake was so rapid that it was limited by the plasma flow rate. It is concluded that the carrier-mediated active transport systems demonstrated in vitro are responsible for the nonlinear pharmacokinetics of ONO-1301.
 ...
PMID:Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist. 949 54


<< Previous 1 2 3 4 5 Next >>